ࡱ>  !bjbj ;}}TQ#4j:,f,#.#.#.#.#.#.#$$'fR#-~~~R##!!!~,#!~,#!!!T=Z[ !##0#!(>(!!n(X"~~!~~~~~R#R#!"~~~#~~~~(~~~~~~~~~ :  Supplementary Table 1. Treatment characteristics of the eligible studies.StudyArm designNACT regimensAgents administration dosageSample size in each armNo. of pCRAft 2010Standard chemotherapetic agents vs. Za-containing regimensTADocetaxel=75 mg/m2, Epirubicin=75 mg/m2192*TAZaDocetaxel=75 mg/m2, Epirubicin =75 mg/m2, Zoledronic acid= 4mg216*Houber 2010Standard chemotherapetic agents vs. Ca-containing regimensTACDocetaxel=75 mg/m2, Epirubicin=50 mg/m2, Cyclophosphamide=500 mg/m2486TACCaDocetaxel=75 mg/m2, Epirubicin=90 mg/m2, Cyclophosphamide=600 mg/m2, Capecitabine=1000 mg/m2412Bernsdorf 2011Standard chemotherapetic agents vs. G-containing regimensACEpirubicin=90 mg/m2, Cyclophosphamide=600 mg/m2415*ACGEpirubicin=90 mg/m2, Cyclophosphamide=600 mg/m2, Gefitinib=250 mg417*Alba 2012Standard chemotherapetic agents vs. P-containing regimensTACDocetaxel=100 mg/m2, Epirubicin=90 mg/m2, Cyclophosphamide=600 mg/m24614TACPDocetaxel=75 mg/m2, Epirubicin=90 mg/m2, Cyclophosphamide=600 mg/m2, Carboplatin=6 AUC4714Gerber 2013Standard chemotherapetic agents vs. B-containing regimensTACDocetaxel=100 mg/m2, Epirubicin=90 mg/m2, Cyclophosphamide=600 mg/m2340112TACBDocetaxel=100 mg/m2, Epirubicin=90 mg/m2, Cyclophosphamide=600 mg/m2, Bevacizumab=15 mg/Kg323140Steger 2014Standard chemotherapetic agents vs. Ca-containing regimensTADocetaxel=75 mg/m2, Epirubicin=75 mg/m26318TACaDocetaxel=75 mg/m2, Epirubicin=75 mg/m2, Capecitabine=1000 mg/m26426Ando 2014Standard chemotherapetic agents vs. P-containing regimensTACFPaclitaxel =80 mg/m2, Epirubicin=100 mg/m2, Cyclophosphamide=500 mg/m2, Florouracil=500 mg/m23810TACFPPaclitaxel=80 mg/m2, Epirubicin=100 mg/m2, Cyclophosphamide=500 mg/m2, Florouracil=500 mg/m2, Carboplatin=5 AUC3723Earl 2014Standard chemotherapetic agents vs. Ge-containing regimensTACPaclitaxel =175 mg/m2, Epirubicin=90 mg/m2, Cyclophosphamide=600 mg/m27323TACGePaclitaxel =175mg/m2, Epirubicin=90mg/m2, Cyclophosphamide=600mg/m2, Gemcitabine=2000 mg/m28427Gonzalez-Angulo 2014Standard chemotherapetic agents vs. E-containing regimensTACFPaclitaxel=80 mg/m2, Epirubicin=100mg/m2, Cyclophosphamide=500 mg/m2, Florouracil=500 mg/m2277TACFEPaclitaxel=80 mg/m2, Epirubicin=100 mg/m2, Cyclophosphamide=500 mg/m2, Florouracil=500 mg/m2, Everolimus=30 mg237von Minckwitz 2014B-containing regimens vs. BP-containing regimensTABPaclitaxel=80 mg/m2, Doxorubicin=20 mg/m2, Bevacizumab=15 mg/kg15767TABPPaclitaxel =80 mg/m2, Doxorubicin=20mg/m2, Bevacizumab=15 mg/kg, Carboplatin=2 AUC15890Earl 2015Standard chemotherapetic agents vs. B-containing regimensTACFDocetaxel=100 mg/m2, Epirubicin=100 mg/m2, Cyclophosphamide=500 mg/m2, Florouracil=500 mg/m212238TACFBDocetaxel=100 mg/m2, Epirubicin=100 mg/m2, Cyclophosphamide=500 mg/m2, Florouracil=500 mg/m2, Bevacizumab=15mg/kg11954Hasegawa 2015Standard chemotherapetic agents vs. Za-containing regimensTACFPaclitaxel=80 mg/m2, Epirubicin=100 mg/m2, Cyclophosphamide=500 mg/m2, Florouracil=500 mg/m2172*TACFZaPaclitaxel=80mg/m2, Epirubicin=100mg/m2, Cyclophosphamide=500mg/m2, Florouracil=500mg/m2, Zoledronic acid=4 mg176*Llombart-Cussac 2015Standard chemotherapetic agents vs. Pi-containing regimensTPaclitaxel=80 mg/m24610TPiPaclitaxel=80 mg/m2, Iniparib=5.6/12.2 mg/kg9417Martinez 2015Standard chemotherapetic agents vs. P-containing regimensTACFPaclitaxel=80 mg/m2, Doxorubicin=50 mg/m2, Cyclophosphamide=500 mg/m2, Florouracil=500 mg/m23112TAPPaclitaxel=80 mg/m2, Doxorubicin=50 mg/m2, Cisplatin=30 mg/m23018Sikov 2015Standard chemotherapetic agents vs. B-containing regimens vs. P-containing regimens vs. BP-containing regimensTACPaclitaxel=80 mg/m2, Doxorubicin=60 mg/m2, Cyclophosphamide=600 mg/m210742TACBPaclitaxel=80 mg/m2, Doxorubicin=60 mg/m2, Cyclophosphamide=500 mg/m2, Bevacizumab=10 mg/kg 10545TACPPaclitaxel=80mg/m2, Doxorubicin=60 mg/m2, Cyclophosphamide= 500mg/m2, Carboplatin=6 AUC11154TACBPPaclitaxel=80 mg/m2, Doxorubicin=60 mg/m2, Cyclophosphamide= 500mg/m2, Bevacizumab=10 mg/kg, Carboplatin=6 AUC11066Nahleh 2016Standard chemotherapetic agents vs. B-containing regimensTACnab-Paclitaxel =100 mg/m2, Doxorubicin=60 mg/m2, Cyclophosphamide=600 mg/m23510TACBnab-Paclitaxel=100 mg/m2, Doxorubicin=60 mg/m2, Cyclophosphamide=600 mg/m2, Bevacizumab=10 mg/kg3219Zhang 2016Standard chemotherapetic agents vs. P-containing regimensTAPaclitaxel=175 mg/m2, Epirubicin=75 mg/m2436TPPaclitaxel=175 mg/m2, Carboplatin=5 AUC4417Rugo 2016Standard chemotherapetic agents vs. PPi-containing regimensTACPaclitaxel=80mg/m2, Doxorubicin=60mg/m2, Cyclophosphamide=600mg/m2215TACPPiPaclitaxel=80 mg/m2, Doxorubicin=60 mg/m2, Cyclophosphamide=600 mg/m2, Carboplatin=6 AUC, Veliparib=50 mg/m23920Enriquez 2017Standard chemotherapetic agents vs. P-containing regimensTACPaclitaxel=80 mg/m2, Adriamycin=60 mg/m2, Cyclophosphamide=600 mg/m2348TPDocetaxel=75mg/m2, Carboplatin=6 AUC2710Gluz 2017Ge-containing regimens vs. P-containing regimensTGenab-Paclitaxel =125 mg/m2, Gemcitabine=1000 mg/m217851TPnab-Paclitaxel =125 mg/m2, Carboplatin=2 AUC14667Jovanovi 2017P-containing regimens vs. PE-containing regimensTPPaclitaxel=80 mg/m2, Cisplatin=25 mg/m24924TPEPaclitaxel=80 mg/m2, Cisplatin=25 mg/m2, Everolimus= 30mg9635Loibl 2018Standard chemotherapetic agents vs. P-containing regimens vs. PPi-containing regimensTACPaclitaxel=80 mg/m2, Doxorubicin=60 mg/m2, Cyclophosphamide=600 mg/m215849TACPPaclitaxel=80 mg/m2, Doxorubicin=60 mg/m2, Cyclophosphamide=600 mg/m2, Carboplatin=6 AUC16092TACPPiPaclitaxel=80 mg/m2, Doxorubicin=60 mg/m2, Cyclophosphamide=600 mg/m2, Carboplatin=6 AUC, Veliparib=50 mg/m2316168Wu 2018Standard chemotherapetic agents vs. P-containing regimensTADocetaxel=75 mg/m2, Epirubicin=80 mg/m2608TAPDocetaxel=75mg/m2, Epirubicin=80mg/m2, Lobaplatin=30 mg/m26124A, anthracyclines; B, bevacizumab; C, cyclophosphamide; Ca, capecitabine; E, everolimus; F, florouracil; G, gefitinib; Ge, gemcitabine; P, platinum salts; Pi,Poly(ADP-ribose) polymerases (PARPs); T, taxanes; Za, zoledronic acid; NA, not available; *pCR defined as ypT0/is. J        ! 5 6 : ; K L c d l m n ƻuululuhl6 KHaJo(h=hH*KHaJh=hKHaJo(h=hKHaJh=hEKHaJo(h=hNKHaJo(h=hAKHaJh=hEKHaJh"hE5KHaJhh5KH\aJo(h=hE5KH\aJhk5KH\aJh=h2JaJ*KLR]k $$1$Ifa$gdEBkd$$IfTl02244 laGT $$1$Ifa$gd6=<gd2J   ! ^PPPPPP $$1$Ifa$gdkdj$$IfTlvֈ(-0  244 laGT! " # $ ) h k n \NNNNNN $$1$Ifa$gd6=<kdP$$IfTl4hֈ(-0  244 laGTn o {   \NNNNNN $$1$Ifa$gdkd'$$IfTl4ֈ(-0  244 laGT     - . 2 3 I J N O b c g h   ! " & ' 6 7 = > ? @         . / : hl6 KHaJo(h=hKHaJo(h=hKHaJh=hH*KHaJQ    i l n \NNNNNN $$1$Ifa$gd6=<kd$$IfTl4vֈ(-0  244 laGTn o ~ \NNNNNN $$1$Ifa$gdkd$$IfTl4vֈ(-0  244 laGT : = @ \NNNNNN $$1$Ifa$gd6=<kd$$IfTl4vֈ(-0  244 laGT@ A K \NNNNNN $$1$Ifa$gdkd$$IfTl4vֈ(-0  244 laGT 3 6 9 \NNNNNN $$1$Ifa$gd6=<kdZ$$IfTl4vֈ(-0  244 laGT9 : F \NNNNNN $$1$Ifa$gd6=<kd1$$IfTl4vֈ(-0  244 laGT:      - . \]abrswxݺh=hM'KHaJh=hM'KHaJo(h=h#eKHaJo(h=hEH*KHaJh=hcNKHaJo(h=hEKHaJI 4 8 < \NNNNNN $$1$Ifa$gd6=<kd$$IfTl4vֈ(-0  244 laGT< = I \NNNNNN $$1$Ifa$gd6=<kd$$IfTl4ֈ(-0  244 laGT \NNNNNN $$1$Ifa$gd6=<kd $$IfTl4ֈ(-0  244 laGTIN\NNNNNN $$1$Ifa$gd6=<kd $$IfTl4vֈ(-0  244 laGT+.1\NNNNNN $$1$Ifa$gd6=<kdd $$IfTl4ֈ(-0  244 laGT%'$%&'+,1267HIMN]^h=h|R/KHaJo(h=h3iKHaJh=h3iKHaJo(h=hEH*KHaJh=hEKHaJh=hM'KHaJo(I12<w{\NNNNNN $$1$Ifa$gd6=<kd; $$IfTl4ֈ(-0  244 laGT-03\NNNNNN $$1$Ifa$gd6=<kd $$IfTl4vֈ(-0  244 laGT34I\NNNNNN $$1$Ifa$gd6=<kd $$IfTl4ֈ(-0  244 laGTadf\NNNNNN $$1$Ifa$gd6=<kd$$IfTl4ֈ(-0  244 laGTfgz\NNNNNN $$1$Ifa$gd6=<kd$$IfTl4ֈ(-0  244 laGT   !&'78;<=LM!"2378NOSTefjk~-.237h=h}0KHaJo(h=h4KHaJo(h=h|R/KHaJh=hEH*KHaJh=h|R/KHaJo(h=hEKHaJHQUX\NNNNNN $$1$Ifa$gd6=<kdn$$IfTl4vֈ(-0  244 laGTXYc\NNNNNN $$1$Ifa$gd6=<kdE$$IfTl4vֈ(-0  244 laGT \NNNNNN $$1$Ifa$gd6=<kd$$IfTl4ֈ(-0  244 laGT47:\NNNNNN $$1$Ifa$gd6=<kd$$IfTl4ֈ(-0  244 laGT789:UVjk:;?@STWX  %&*+;<@AOPTU ߻߻߻߻߻߻߻߻߻߻߻߯߯߯h=h5KHaJo(h=h;KHaJo(h=h}0KHaJo(h=hEH*KHaJh=hEKHaJhl6 KHaJo(h=hEKHaJo(E:;<=D\NNNNNN $$1$Ifa$gd6=<kd$$IfTl4ֈ(-0  244 laGT   #&\NNNNNN $$1$Ifa$gd6=<kd$$IfTl4ֈ(-0  244 laGT&'()-Z]`\NNNNNN $$1$Ifa$gd6=<kdx$$IfTl4ֈ(-0  244 laGT`ao \NNNNNN $$1$Ifa$gd6=<kdO$$IfTl4ֈ(-0  244 laGTVY\\NNNNNN $$1$Ifa$gd6=<kd&$$IfTl4ֈ(-0  244 laGT\]h!%(\NNNNNN $$1$Ifa$gd6=<kd$$IfTl4vֈ(-0  244 laGT()*+0\NNNNNN $$1$Ifa$gd6=<kd$$IfTl4vֈ(-0  244 laGT =>BCQRSTXYoptu&'()-.ABIJZ[^_opst  2378ƺƺݺh=hEKHaJo(h=h5KHaJh=h KHaJo(h=hEH*KHaJh=h5KHaJo(h=hEKHaJI\NNNNNN $$1$Ifa$gd6=<kd$$IfTl4ֈ(-0  244 laGTtx{\NNNNNN $$1$Ifa$gd6=<kd$$IfTl4vֈ(-0  244 laGT{|\NNNNNN $$1$Ifa$gd6=<kdY$$IfTl4ֈ(-0  244 laGT \NNNNNN $$1$Ifa$gd6=<kd0$$IfTl4vֈ(-0  244 laGT8HIMNdeijz{~()$%67;<h=hDKHaJo(h=hDKHaJh=h:P\KHaJo(h=hTKHaJo(h=hEKHaJo(h=h KHaJh=hEH*KHaJh=h KHaJo(h=hEKHaJ;\NNNNNN $$1$Ifa$gd6=<kd$$IfTl4ֈ(-0  244 laGT-03\NNNNNN $$1$Ifa$gd6=<kd$$IfTl4ֈ(-0  244 laGT34>z~\NNNNNN $$1$Ifa$gd6=<kd$$IfTl4ֈ(-0  244 laGT=@C\NNNNNN $$1$Ifa$gd6=<kd$$IfTl4vֈ(-0  244 laGTCDR\NNNNNN $$1$Ifa$gd6=<kdc $$IfTl4ֈ(-0  244 laGTXZ6<DFdfln#$()DEIJXY]^knƻݯݘh=h!KHaJo(h=h;sKHaJh=hV"KHaJo(h=hEKHaJo(h=h4[KHaJh=h4[KHaJo(h=hDKHaJh=hEH*KHaJh=hDKHaJo(h=hEKHaJ7 \NNNNNN $$1$Ifa$gd6=<kd:!$$IfTl4vֈ(-0  244 laGT,\NNNNNN $$1$Ifa$gd6=<kd"$$IfTl4ֈ(-0  244 laGT  nv|\NNNNNN $$1$Ifa$gd6=<kd"$$IfTl4ֈ(-0  244 laGT|~*-0\NNNNNN $$1$Ifa$gd6=<kd#$$IfTl4ֈ(-0  244 laGT01237qtw\NNNNNN $$1$Ifa$gd6=<kd$$$IfTl4ֈ(-0  244 laGTwx#'*\NNNNNN $$1$Ifa$gd6=<kdm%$$IfTl4vֈ(-0  244 laGT!"?@DEUVZ[qrvw    c d h i x y } ~ !!!!!!hl6 h2JaJ h=hvZhl6 hl6 KHaJhl6 KHaJo(h=h32KHaJo(h=h!KHaJo(h=hEH*KHaJh=h4fKHaJo(h=hEKHaJ>*+,-2\NNNNNN $$1$Ifa$gd6=<kdD&$$IfTl4vֈ(-0  244 laGT  \NNNNNN $$1$Ifa$gd6=<kd'$$IfTl4vֈ(-0  244 laGT   T W  \NNNNNN $$1$Ifa$gd6=<kd'$$IfTl4ֈ(-0  244 laGT \NNNNNN $$1$Ifa$gd6=<kd($$IfTl4ֈ(-0  244 laGT !\N $$1$Ifa$gd6=<kd)$$IfTl4vֈ(-0  244 laGT!!!!gd2JBkd*$$IfTlv02244 laGT9182P0:p6=<A .!"#$%S h$$IfG!vh52#v2:V l2,52/ 4aGT$$IfG!vh5 5 5555#v #v #v#v#v#v:V lv2,5 5 5555/ / 4aGT$$IfG!vh5 5 5555#v #v #v#v#v#v:V l4h2++,5 5 55554aGT$$IfG!vh5 5 5555#v #v #v#v#v#v:V l42++,5 5 55554aGT$$IfG!vh5 5 5555#v #v #v#v#v#v:V l4v2++,5 5 55554aGT$$IfG!vh5 5 5555#v #v #v#v#v#v:V l4v2++,5 5 55554aGT$$IfG!vh5 5 5555#v #v #v#v#v#v:V l4v2++,5 5 55554aGT$$IfG!vh5 5 5555#v #v #v#v#v#v:V l4v2++,5 5 55554aGT$$IfG!vh5 5 5555#v #v #v#v#v#v:V l4v2++,5 5 55554aGT$$IfG!vh5 5 5555#v #v #v#v#v#v:V l4v2++,5 5 55554aGT$$IfG!vh5 5 5555#v #v #v#v#v#v:V l4v2++,5 5 55554aGT$$IfG!vh5 5 5555#v #v #v#v#v#v:V l42++,5 5 55554aGT$$IfG!vh5 5 5555#v #v #v#v#v#v:V l42++,5 5 55554aGT$$IfG!vh5 5 5555#v #v #v#v#v#v:V l4v2++,5 5 55554aGT$$IfG!vh5 5 5555#v #v #v#v#v#v:V l42++,5 5 55554aGT$$IfG!vh5 5 5555#v #v #v#v#v#v:V l42++,5 5 55554aGT$$IfG!vh5 5 5555#v #v #v#v#v#v:V l4v2++,5 5 55554aGT$$IfG!vh5 5 5555#v #v #v#v#v#v:V l42++,5 5 55554aGT$$IfG!vh5 5 5555#v #v #v#v#v#v:V l42++,5 5 55554aGT$$IfG!vh5 5 5555#v #v #v#v#v#v:V l42++,5 5 55554aGT$$IfG!vh5 5 5555#v #v #v#v#v#v:V l4v2++,5 5 55554aGT$$IfG!vh5 5 5555#v #v #v#v#v#v:V l4v2++,5 5 55554aGT$$IfG!vh5 5 5555#v #v #v#v#v#v:V l42++,5 5 55554aGT$$IfG!vh5 5 5555#v #v #v#v#v#v:V l42++,5 5 55554aGT$$IfG!vh5 5 5555#v #v #v#v#v#v:V l42++,5 5 55554aGT$$IfG!vh5 5 5555#v #v #v#v#v#v:V l42++,5 5 55554aGT$$IfG!vh5 5 5555#v #v #v#v#v#v:V l42++,5 5 55554aGT$$IfG!vh5 5 5555#v #v #v#v#v#v:V l42++,5 5 55554aGT$$IfG!vh5 5 5555#v #v #v#v#v#v:V l42++,5 5 55554aGT$$IfG!vh5 5 5555#v #v #v#v#v#v:V l4v2++,5 5 55554aGT$$IfG!vh5 5 5555#v #v #v#v#v#v:V l4v2++,5 5 55554aGT$$IfG!vh5 5 5555#v #v #v#v#v#v:V l42++,5 5 55554aGT$$IfG!vh5 5 5555#v #v #v#v#v#v:V l4v2++,5 5 55554aGT$$IfG!vh5 5 5555#v #v #v#v#v#v:V l42++,5 5 55554aGT$$IfG!vh5 5 5555#v #v #v#v#v#v:V l4v2++,5 5 55554aGT$$IfG!vh5 5 5555#v #v #v#v#v#v:V l42++,5 5 55554aGT$$IfG!vh5 5 5555#v #v #v#v#v#v:V l42++,5 5 55554aGT$$IfG!vh5 5 5555#v #v #v#v#v#v:V l42++,5 5 55554aGT$$IfG!vh5 5 5555#v #v #v#v#v#v:V l4v2++,5 5 55554aGT$$IfG!vh5 5 5555#v #v #v#v#v#v:V l42++,5 5 55554aGT$$IfG!vh5 5 5555#v #v #v#v#v#v:V l4v2++,5 5 55554aGT$$IfG!vh5 5 5555#v #v #v#v#v#v:V l42++,5 5 55554aGT$$IfG!vh5 5 5555#v #v #v#v#v#v:V l42++,5 5 55554aGT$$IfG!vh5 5 5555#v #v #v#v#v#v:V l42++,5 5 55554aGT$$IfG!vh5 5 5555#v #v #v#v#v#v:V l42++,5 5 55554aGT$$IfG!vh5 5 5555#v #v #v#v#v#v:V l4v2++,5 5 55554aGT$$IfG!vh5 5 5555#v #v #v#v#v#v:V l4v2++,5 5 55554aGT$$IfG!vh5 5 5555#v #v #v#v#v#v:V l4v2++,5 5 55554aGT$$IfG!vh5 5 5555#v #v #v#v#v#v:V l42++,5 5 55554aGT$$IfG!vh5 5 5555#v #v #v#v#v#v:V l42++,5 5 5555/ 4aGT$$IfG!vh5 5 5555#v #v #v#v#v#v:V l4v2++,5 5 5555/ 4aGTh$$IfG!vh52#v2:V lv2,52/ 4aGTb 2 0@P`p2( 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p8XV~PJ_HmH nH sH tH R`R Normal $1$a$ CJKH_HaJmH nHsH tHDA D Default Paragraph FontRi@R  Table Normal4 l4a (k (No List Z/Z /,font315567>*CJOJQJS*Y(\]^JaJo(phZ/Z /,font415567>*CJOJQJS*Y(\]^JaJo(phZ/Z 6=<font015567>*CJOJQJS*Y(\]^JaJo(phPK![Content_Types].xmlj0Eжr(΢Iw},-j4 wP-t#bΙ{UTU^hd}㨫)*1P' ^W0)T9<l#$yi};~@(Hu* Dנz/0ǰ $ X3aZ,D0j~3߶b~i>3\`?/[G\!-Rk.sԻ..a濭?PK!֧6 _rels/.relsj0 }Q%v/C/}(h"O = C?hv=Ʌ%[xp{۵_Pѣ<1H0ORBdJE4b$q_6LR7`0̞O,En7Lib/SeеPK!kytheme/theme/themeManager.xml M @}w7c(EbˮCAǠҟ7՛K Y, e.|,H,lxɴIsQ}#Ր ֵ+!,^$j=GW)E+& 8PK!Ptheme/theme/theme1.xmlYOo6w toc'vuر-MniP@I}úama[إ4:lЯGRX^6؊>$ !)O^rC$y@/yH*񄴽)޵߻UDb`}"qۋJחX^)I`nEp)liV[]1M<OP6r=zgbIguSebORD۫qu gZo~ٺlAplxpT0+[}`jzAV2Fi@qv֬5\|ʜ̭NleXdsjcs7f W+Ն7`g ȘJj|h(KD- dXiJ؇(x$( :;˹! I_TS 1?E??ZBΪmU/?~xY'y5g&΋/ɋ>GMGeD3Vq%'#q$8K)fw9:ĵ x}rxwr:\TZaG*y8IjbRc|XŻǿI u3KGnD1NIBs RuK>V.EL+M2#'fi ~V vl{u8zH *:(W☕ ~JTe\O*tHGHY}KNP*ݾ˦TѼ9/#A7qZ$*c?qUnwN%Oi4 =3ڗP 1Pm \\9Mؓ2aD];Yt\[x]}Wr|]g- eW )6-rCSj id DЇAΜIqbJ#x꺃 6k#ASh&ʌt(Q%p%m&]caSl=X\P1Mh9MVdDAaVB[݈fJíP|8 քAV^f Hn- "d>znNJ ة>b&2vKyϼD:,AGm\nziÙ.uχYC6OMf3or$5NHT[XF64T,ќM0E)`#5XY`פ;%1U٥m;R>QD DcpU'&LE/pm%]8firS4d 7y\`JnίI R3U~7+׸#m qBiDi*L69mY&iHE=(K&N!V.KeLDĕ{D vEꦚdeNƟe(MN9ߜR6&3(a/DUz<{ˊYȳV)9Z[4^n5!J?Q3eBoCM m<.vpIYfZY_p[=al-Y}Nc͙ŋ4vfavl'SA8|*u{-ߟ0%M07%<ҍPK! ѐ'theme/theme/_rels/themeManager.xml.relsM 0wooӺ&݈Э5 6?$Q ,.aic21h:qm@RN;d`o7gK(M&$R(.1r'JЊT8V"AȻHu}|$b{P8g/]QAsم(#L[PK-![Content_Types].xmlPK-!֧6 +_rels/.relsPK-!kytheme/theme/themeManager.xmlPK-!Ptheme/theme/theme1.xmlPK-! ѐ' theme/theme/_rels/themeManager.xml.relsPK]   : 7 8!#).6;AH! n  n @ 9 < 13fX:&`\({3C|0w* !! !"$%&'(*+,-/012345789:<=>?@BCDEFGIJKLMN8@0(  B S  ? OLE_LINK1 OLE_LINK2 OLE_LINK3 OLE_LINK4 OLE_LINK5.. 22 $()2=GS]ou   *Q]ox)2Tc*dn `b=C  9 D P Z k t ) 4   $ . V a m x  ) = C ) , B J CL]bwLW|lw48be*3 GJ LU`jx}W`ku $)49BDFhoL)h{ i~:K3F4<=IIN+12<w{-34Ia z Q X Y c   4 D & ) - Z ` a o V\]h!(+0t{| -34>z~=CDR  GK}*037qwx#*-2 TW]<(ev0#i?qUv*)4`M'l6 ;Tk/,|R/}06=<AENcNvZ4[:P\W^t`#e4fTg3i@ti;shu!$32= gV"2J5Iw";bD@JJJJ(h@hh<@UnknownG*Ax Times New Roman5Symbol3. *Cx Arial;(SimSun[SOA BCambria Math qh\-fGxIeg+ -+ -!-!),.:;?]}    & 6"0000 0 0 00000 =@\]^([{  0 0 00000;[r3KX ?u2!xxTable 2 Sky123.Org Olga KrasnovaOh+'0   @ L X dpxTable 2 Sky123.Org Normal.dotmOlga Krasnova29Microsoft Office Word@a@>mZ@5@Y[+՜.+,0 hp  China-  Table 2 Title  !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOQRSTUVWXYZ[\]^_`abcdeghijklmnopqrstuvwxyz|}~Root Entry FCZ[Data P*1Tablef(WordDocument;SummaryInformation({DocumentSummaryInformation8CompObjy  F'Microsoft Office Word 97-2003 Document MSWordDocWord.Document.89q